NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout

    India
    Business
    World
    Politics
    Sports
    Technology
    Entertainment
    Auto
    Lifestyle
    Inspirational
    Career
    Bengaluru
    Delhi
    Mumbai

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
    Home / News / Technology News / Moderna's COVID-19 vaccine: When will it be available?
    Next Article
    Moderna's COVID-19 vaccine: When will it be available?

    Moderna's COVID-19 vaccine: When will it be available?

    By Shubham Sharma
    Jun 09, 2020
    12:33 am

    What's the story

    In the race to develop a vaccine for COVID-19, Moderna Therapeutics is seen as one of the fastest-moving players.

    The biotech company has developed a vaccine candidate and is quickly moving through the trial phase, giving a ray of hope to the whole world.

    But, the question is, can their formula generate an immune response, and when will it be available?

    Let's find out.

    Vaccine

    Moderna's genetic code-based mRNA-1273 vaccine

    Moderna's scientists, working in partnership with the US National Institute of Allergy and Infectious Diseases, have developed a vaccine called mRNA-1273.

    The injection carries a segment of genetic code copied from the virus's spike protein, the appendage it uses to enter cells and replicate.

    It is different from conventional vaccines that use a weakened/killed strain of the virus they are designed to fight off.

    Working

    So, how does it work?

    When the vaccine is injected, the genetic code of the spike protein goes into the body.

    As this happens, the body learns to recognize the coronavirus and generates antibodies, proteins secreted by immune cells called B lymphocytes, required to fight it off.

    This way, when the active version of the virus attacks, the immune system is already primed to act against it.

    Work

    Effectiveness and safety is currently being judged

    The vaccine has passed the development/exploratory phase and is confirmed to be working in lab tests and models.

    But, to judge its efficacy and safety for widespread public use, scientists are carrying out trials in the US.

    The testing phase includes four main stages: pre-clinical animal trials, and Phase 1, 2, and 3 of clinical human trials.

    Pre-clinical result

    So far, the results have been promising

    In the pre-clinical trials, carried out simultaneously with Phase-1 clinical trials, mRNA-1273 was tested on mice and was able to generate enough antibodies to fight off the novel coronavirus and prevent it from replicating.

    Interestingly, the level of antibodies noted in these animal tests was also found to be consistent with the levels generated from the vaccine in humans, during Phase-1 trials.

    Phase-1

    Results from Phase-1 human trials

    In Phase-1 clinical trials, which started on March 16, the experimental vaccine was given in three separate doses - 25 micrograms, 100 micrograms, and 250 micrograms - to 45 people (each dose for 15) at a gap of 28 days.

    The early results of these tests revealed that the vaccine produced detectable antibodies in all the volunteers, with a dose-dependent increment in immunogenicity.

    Antibodies

    Antibody levels similar to those seen in recovered patients

    Moderna said that the participants who got the 25 micrograms shot generated antibodies at levels seen in the blood of recovered COVID-19 patients, while the 100 micrograms group had antibodies that "significantly exceeded levels" seen in recovered cases.

    Also, the vaccine was able to produce neutralizing antibodies in at least eight of the participants (four each from 25 and 100 micrograms group).

    Phase-2

    Phase-2 of human trials are currently in progress

    With the promising results from pre-clinical and Phase-1 of clinical trials, Moderna has been cleared for Phase-2 of clinical human trials, which started just last week.

    In these tests, the vaccine will be tested on 600 adults and the immune response - the antibodies - generated in their bodies will be assessed to determine the effectiveness and safety of the vaccine.

    Phase-3

    Then, Phase-3 and approval process would follow

    Once Phase-2's results are available, which are expected by July, the vaccine candidate would go into the final phase, which will be a randomized placebo-controlled test involving 30,000 individuals from around the world.

    This phase will be aimed at generating as much data as possible on the efficacy and safety of the vaccine and lining it up for FDA approval by early 2021.

    Availability

    Availability in early-2021 possible

    If all goes according to the plan, the mRNA-1273 vaccine could become available for emergency use in the first half of 2021.

    Moderna has already partnered with Swiss drugmaker Lonza to set up manufacturing and is hoping to start production as early as July to have millions of doses ready for distribution by the time Phase-3 trials end and the vaccine is approved.

    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Latest
    COVID-19
    Moderna Therapeutics
    Moderna Inc

    Latest

    Valid Green Card holders might be deported for this reason United States of America
    'Women in Pahalgam lacked heroic qualities': BJP MP's controversial remark Akhilesh Yadav
    Varun-Dinesh Vijan may reunite for mytho-horror drama: What to expect Anees Bazmee
    LIC has set Guinness World Record for selling insurance policies Life Insurance Corporation of India

    COVID-19

    Lockdown extended in containment zones till June 30: Home Ministry Coronavirus
    Coronavirus: India's tally crosses 1.81 lakh; biggest spike in infections Madhya Pradesh
    #MannKiBaat: Poor, migrants suffered most due to coronavirus, says Modi Narendra Modi
    Nearly 30% COVID-19 patients were asymptomatic in India: ICMR Indian Council of Medical Research (ICMR)

    Moderna Therapeutics

    US begins human trials of coronavirus vaccine: Details here Health & Wellness
    COVID-19 vaccine not guaranteed, says leading world health expert World Health Organization
    Moderna's COVID-19 vaccine gets FDA nod for phase 2 trial Oxford University
    Moderna's COVID-19 vaccine shows 'positive' results in human trials United States of America

    Moderna Inc

    Why the vaccine for COVID-19 is still several months away Coronavirus
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2025